CME in Minutes: Education in Oncology & Hematology: Recent Episodes
Answers in CME
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Please visit answersincme.com/BHU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lymphoma discusses the treatment landscape for CD30-positive peripheral T-cell lymphoma (PTCL). Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations for frontline treatment of PTCL; Describe the clinical evidence informing the use of CD30-directed therapy in frontline treatment of PTCL; and Outline considerations to optimize outcomes with CD30-directed therapy for frontline treatment of patients with PTCL.
Please visit answersincme.com/93496951-replay2860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the clinical implications of the latest data for HER2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC; and Describe practical, data-driven approaches to effectively integrate current and emerging ADCs into the management of advanced NSCLC.
Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.
Please visit answersincme.com/93496951-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the significance of the latest data for TROP2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; and Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC.
Please visit answersincme.com/UCA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the management of advanced basal cell carcinoma (BCC) with systemic therapy. Upon completion of this activity, participants should be better able to: Identify patients with BCC who are candidates for a systemic approach to treatment; Review the clinical implications of the evidence on approved and emerging systemic therapies in patients with advanced BCC; and Describe practical strategies to optimize systemic treatment over the long term for patients with advanced BCC. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/TBY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in colorectal cancer discuss management of patients with metastatic disease in the third line and beyond. Upon completion of this activity, participants should be better able to: Identify guideline recommendations for later-line treatments for patients with metastatic colorectal cancer (mCRC); Review the clinical implications of the latest evidence for later-line treatments for patients with mCRC; and Outline evidence-based approaches to improve long-term response rates in later-line treatment of mCRC.
Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the treatment of resectable melanoma; Describe the key adverse events associated with adjuvant immunotherapy for the treatment of resectable melanoma; Outline evidence-based, patient centric strategies to optimize the benefit-to-risk impact of adjuvant immunotherapy in resectable melanoma care
Please visit answersincme.com/ZFZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of immunotherapy in neoadjuvant treatment of early breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for adding immunotherapy to chemotherapy in the neoadjuvant treatment of early HR-positive, HER2-negative breast cancer; Identify the clinical implications of the latest data for neoadjuvant treatment with immunotherapy plus chemotherapy regimens in early HR-positive, HER2-negative breast cancer; Describe the role that neoadjuvant, immunotherapy-containing regimens might play in the future management of patients with early HR-positive, HER2-negative breast cancer, including high risk patients.
Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guideline recommendations for the treatment of advanced BCC; Identify the clinical implications of the available evidence evaluating immunotherapy options for patients with advanced BCC; and Outline real-world considerations for the integration of immunotherapy into practice for the management of advanced BCC. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing antibody-drug conjugates (ADCs) targeting B7-H3 as treatment for extensive-stage small-cell lung cancer (ES-SCLC); Review the preliminary efficacy and safety data for emerging B7-H3–directed ADCs for the treatment of pretreated ES-SCLC; and Describe key clinical considerations for the future use of B7-H3–directed ADCs in ES-SCLC.
Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/ZVJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the management of metastatic colorectal cancer (mCRC) discusses treatment strategies to enhance patient outcomes during later-line therapy. Upon completion of this activity, participants should be better able to: Identify guideline recommendations for later-line treatments for patients with mCRC; Describe recent evidence for later-line treatments for patients with mCRC, including evidence informing treatment sequencing; and Review evidence-based, patient-centered approaches to manage adverse events for patients with mCRC receiving later-line treatment.
Please visit answersincme.com/TBW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer offers guidance for determining HER2 status in patients with advanced breast cancer, and shares insights on clinical data and strategies to optimize the use of antibody-drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Review the guideline recommendations to optimize the identification of patients with HER2-low advanced breast cancer; Outline the clinical implications of the most recent data evaluating the use of available ADCs in the treatment of HER2-low advanced breast cancer; and Identify practical strategies to optimize outcomes with ADC treatment for real-world patient populations with HER2-low advanced breast cancer.
Please visit answersincme.com/CFN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in oncology discuss current and emerging treatments for unresectable stage I to III EGFR mutation–positive non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Review best practices for integrating biomarker testing into practice for stage I to III NSCLC; Describe the clinical profiles of current and emerging therapeutic approaches for the management of stage I to III NSCLC; and Outline multidisciplinary strategies to optimize the integration of a targeted approach into clinical practice for patients with stage I to III NSCLC.
Please visit answersincme.com/VWG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses patient selection and treatment for myelodysplastic syndromes. Upon completion of this activity, participants should be better able to: Identify practical strategies for risk stratification and mutation analysis of patients with myelodysplastic syndromes (MDS) to enable risk-adapted therapy; Review the clinical profiles of conventional and newly approved therapies to treat anemia in patients with lower-risk MDS; and Describe the impact of recent data on treatment practices for the management of anemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk MDS.
Please visit answersincme.com/UYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology and digestive oncology discusses guidance for use of TKI therapy in advanced hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Describe evidence for the optimal use of tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC); Identify patient- and disease-based factors which guide the use of TKI therapy for the treatment of advanced HCC; and Outline strategies to develop personalized treatment plans to maximize clinical outcomes using TKI therapies in the treatment of advanced HCC.
Please visit answersincme.com/YSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the practical implications of emerging TROP2 antibody–drug conjugates (ADCs) for the management of advanced or metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Discuss the rationale for targeting TROP2 in patients with advanced or metastatic NSCLC; Review the clinical profiles of emerging ADCs targeting TROP2 in patients with advanced or metastatic NSCLC; and Identify clinical strategies to optimize management of patients with advanced NSCLC treated with TROP2-directed ADCs, as they become available.
Please visit answersincme.com/DMQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the role of CELMoDs in overcoming IMiD resistance in earlier lines of therapy for multiple myeloma. Upon completion of this activity, participants should be better able to: Explain the biologic rationale for investigating novel CELMoDs in earlier lines of therapy in patients with multiple myeloma (MM); Review the clinical significance of late-stage trials of emerging CELMoDs in the maintenance and earlier-relapse settings in patients with MM; and Outline the clinical considerations for integrating novel CELMoDs in the maintenance and earlier-relapse settings in the future treatment landscape of MM.
Please visit answersincme.com/UWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses chemoimmunotherapy treatment of advanced squamous cell non-small cell lung cancer without molecular alterations. Upon completion of this activity, participants should be better able to: Describe the clinical profiles of approved chemoimmunotherapy combinations for treatment of patients with advanced squamous cell non-small cell lung cancer (NSCLC) without molecular alterations; Review clinical factors for individualizing first-line treatment of patients with advanced squamous cell NSCLC; and Identify real-world factors that impact treatment selection for patients with advanced squamous cell NSCLC. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/CKZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal oncology discusses patient-centered approaches to the diagnosis and treatment of biliary tract cancer. Upon completion of this activity, participants should be better able to: Recognize the importance of achieving an accurate diagnosis of biliary tract cancer (BTC); Outline strategies for reaching a diagnosis of BTC, including cholangiocarcinoma; and Describe patient-centered approaches to enhance outcomes for patients undergoing a diagnostic work-up for BTC.
Please visit answersincme.com/HRY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses the use of gene therapy for the treatment of sickle cell disease (SCD). Upon completion of this activity, participants should be better able to: Identify the rationale for the use of gene therapy in sickle cell disease; Review the clinical significance of the latest trial data for gene therapy in sickle cell disease; and Outline considerations to optimize the use of gene therapy in patients with sickle cell disease.
Please visit answersincme.com/VMK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses the use of novel therapies for patients with transfusion-dependent beta thalassemia. Upon completion of this activity, participants should be better able to: Describe the limitations of ongoing transfusions for patients with transfusion-dependent beta thalassemia (TDT); Review the evidence on novel therapies for TDT; and Outline shared decision-making strategies for the potential use of novel therapies for patients with TDT.
Please visit answersincme.com/AEP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloma discusses strategies to integrate novel anti-CD38 monoclonal antibody (mAb)-based triplet regimens into care plans for patients with early relapse multiple myeloma (MM). Upon completion of this activity, participants should be better able to: Review the latest evidence-based guideline recommendations for the treatment of early relapse MM; Outline the clinical implications of the latest evidence for anti-CD38 mAb-based triplet regimens in the treatment of early relapse MM; and Identify strategies to optimally integrate novel anti-CD38 mAb-based triplet regimens into treatment plans for patients with early relapse MM.
Please visit answersincme.com/SWS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver cancer discusses emerging transarterial chemoembolization (TACE) plus immunotherapy–based combinations in intermediate-stage hepatocellular carcinoma (iHCC). Upon completion of this activity, participants should be better able to: Identify the limitations of currently available therapeutic approaches for patients with locoregional therapy–eligible, unresectable hepatocellular carcinoma (HCC); Describe the clinical significance of combination therapies that involve transarterial chemoembolization (TACE) and immunotherapy for patients with intermediate HCC (iHCC); and Review clinical strategies to integrate TACE plus immunotherapy–based combination regimens into the treatment paradigm for patients with iHCC, based on the preliminary data.
Please visit answersincme.com/TSH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of metastatic colorectal cancer (mCRC) discuss sequencing strategies to enhance patient quality of life during later-line treatment. Upon completion of this activity, participants should be better able to: Describe the latest data for later-line treatment sequencing for patients with mCRC; Outline evidence-based strategies to optimally sequence later-line treatment options for mCRC; and Explain tactics for addressing quality of life and survivorship with patients in later lines of treatment for mCRC.
Please visit answersincme.com/YFE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses populations at high risk for cervical cancer and how to apply clinical advances and evolve care in locally advanced disease. Upon completion of this activity, participants should be better able to: Identify populations at high risk of developing cervical cancer; Describe strategies to improve uptake of routine screening for cervical cancer, particularly in high-risk populations; and Outline clinical advances that may evolve the care of patients with newly diagnosed high-risk locally advanced cervical cancer.
Please visit answersincme.com/DDF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in advanced gastric cancer discuss the rationale for testing for HER2 status in patients with advanced gastric cancer and how to optimize care based on the latest clinical evidence. Upon completion of this activity, participants should be better able to: Recognize the rationale for testing for HER2 status in patients with pretreated advanced gastric cancer; Translate the latest clinical evidence on testing to guide selection of HER2-targeted treatments for advanced gastric cancer; and Outline practical multidisciplinary approaches to optimize personalized care of patients with previously treated HER2-positive advanced gastric cancer to enhance health-related quality of life.
Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.
Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.
Please visit answersincme.com/GTJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses endocrine receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Upon completion of this activity, participants should be better able to: Review how the evolving concept of ER sensitivity is relevant to therapeutic decision-making in patients with ER-positive, HER2-negative advanced breast cancer; Describe the clinical profiles of approved and emerging therapeutic options for ER-positive, HER2-negative advanced breast cancer post–cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor use; Identify clinical strategies to optimize the integration of mutational testing into practice for ER-positive, HER2-negative advanced breast cancer; and Outline a personalized approach to therapeutic decision-making to enhance real-world outcomes in ER-positive, HER2-negative advanced breast cancer after initial CDK4/6 inhibitor therapy.
Please visit answersincme.com/XXZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human papillomavirus (HPV) vaccination in males to reduce the burden of HPV-related cancers. Upon completion of this activity, participants should be better able to: Recognize the rationale for vaccination against HPV infection in the male population; Describe the clinical evidence for the guideline-recommended HPV vaccines; and Outline strategies to enhance acceptance of HPV vaccination among the male population.
Please visit answersincme.com/MVB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology and a patient advocate discuss strategies to optimize care for patients with metastatic breast cancer using antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Identify the rationale for targeted antibody-drug conjugates (ADCs) in the treatment of patients with metastatic breast cancer (mBC); Review strategies to enhance safety of the available ADCs for the treatment of mBC; and Outline patient-focused strategies to optimize the use of ADCs in appropriate patients with mBC.
Please visit answersincme.com/TAR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the integration of perioperative immunotherapy-based regimens for the treatment of resectable non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of neoadjuvant followed by adjuvant immunotherapy-based regimens in patients with resectable NSCLC; Describe current evidence on the use of neoadjuvant plus adjuvant immunotherapy in patients with resectable NSCLC; and Outline practical strategies to integrate neoadjuvant plus adjuvant immunotherapy-based regimens into the treatment plan for appropriate patients with resectable NSCLC.
Please visit answersincme.com/PQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in squamous cell carcinoma of the head and neck (SCCHN) discusses the clinical potential of antagonists of inhibitor of apoptosis proteins (IAPs) for unresected, locally advanced SCCHN. Upon completion of this activity, participants should be better able to: Identify the rationale for investigating the use of antagonists of inhibitor of apoptosis proteins (IAPs) in the treatment of unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN); Discuss the latest efficacy and safety data for emerging IAP antagonists for the treatment of unresected LA SCCHN; and Outline clinical considerations for future use of IAP antagonists in unresected LA SCCHN.
Please visit answersincme.com/HRM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cancerous lymphoma discusses EZH2 and EZH1 inhibitors for the management of relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas. Upon completion of this activity, participants should be better able to: Describe the rationale for exploring EZH 2 and EZH1 inhibitors for the management of relapsed or refractory (R/R) B-cell and T-cell non-Hodgkin lymphomas (NHLs); Explain the mechanism of action (MOA) of EZH2 and EZH1 inhibition; and Review the clinical profiles of approved and emerging EZH2 and EZH1 inhibitors for R/R B-cell and T-cell NHLs.
Please visit answersincme.com/XHR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in follicular lymphoma discuss the integration of bispecific antibodies into the treatment of relapsing/refractory follicular lymphoma. Upon completion of this activity, participants should be better able to: Review the clinical profiles of novel CD20 x CD3 bispecific antibodies (BsAbs) for relapsing/refractory follicular lymphoma (R/R FL); Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL; and Outline evidence-based multidisciplinary strategies for optimal integration of BsAbs in the treatment plans of patients with R/R FL.
Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.
Please visit answersincme.com/GXD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic oncology discusses the evolving role of antibody-drug conjugates (ADCs) in HER2-expressing solid tumors. Upon completion of this activity, participants should be better able to: Recognize the role of human epidermal growth factor receptor 2 (HER2) in the pathogenesis of various solid tumors; Describe strategies to optimize HER2 biomarker testing in patients with various solid tumors; Review the evidence for HER2-directed antibody-drug conjugates (ADCs) that have demonstrated benefits in multiple types of HER2-expressing solid tumors; and Outline practical approaches to enhance outcomes for patients receiving HER2-directed ADCs for various solid tumors.
Please visit answersincme.com/AUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of dual immunotherapeutic approaches to the management of advanced melanoma. Upon completion of this activity, participants should be better able to: Review the clinical goals of patients with advanced melanoma receiving immunotherapy-based treatment; Describe the long-term clinical profiles of dual immunotherapeutic approaches to the management of advanced melanoma; and Outline evidence-based, immunotherapy-focused treatment plans for appropriate patients with advanced melanoma to optimize long-term patient outcomes.
Please visit answersincme.com/NRW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the optimization of care for patients with relapsed/refractory follicular lymphoma (R/R FL) and treatment with bispecific antibodies (BsAbs). Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BsAbs in patients with R/R FL; Review the clinical profiles of novel anti-CD20 × CD3 BsAbs for R/R FL; and Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL.
Please visit answersincme.com/EFR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver disease discusses management of unresectable hepatocellular carcinoma through multiple lines of therapy. Upon completion of this activity, participants should be better able to: Identify clinical signs of progression on treatment for unresectable hepatocellular carcinoma (HCC) to enhance timely use of a sequential therapy; Describe the clinical impact of tyrosine kinase inhibitors for the real-world treatment of unresectable HCC; and Outline real-world clinical strategies to maximize the long-term treatment plan for patients with unresectable HCC through multiple lines of therapy.
Please visit answersincme.com/DTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and the future use of CAR T-cell therapies. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs in the management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); Describe the clinical evidence of novel and emerging therapies being investigated to address unmet therapeutic needs in the management of CLL/SLL; and Outline considerations for optimizing the future use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with relapsed/refractory CLL/SLL.
Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.
Please visit answersincme.com/QHX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal oncology discusses frontline chemoimmunotherapeutic regimens for unresectable advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be better able to: Review guideline-recommended preferred frontline treatment regimens for unresectable advanced gastric or GEJ adenocarcinoma; Discuss clinical profiles of approved and late-stage emerging frontline immunotherapy-based chemotherapy combination regimens for unresectable advanced gastric or GEJ adenocarcinoma; and Outline practical considerations for optimizing treatment with frontline immunotherapy-based chemotherapy combination regimens in patients with unresectable advanced gastric or GEJ adenocarcinoma.
Please visit answersincme.com/VVM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the relevance of real-world evidence on the frontline use of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Recognize ways that good quality real-world evidence (RWE) can complement findings from clinical trials in patients with HR+/HER2- metastatic breast cancer (mBC); Outline the clinical relevance of incorporating RWE on the frontline use of CDK4/6 inhibitors into shared decision-making with patients who have HR+/HER2- mBC; and Describe patient-centered strategies to integrate RWE into clinical decision-making discussions with patients who have HR+/HER2- mBC.
Please visit answersincme.com/TAJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatocellular carcinoma (HCC) discusses the data for use of first-line immunotherapy-based combination regimens in patients with unresectable HCC. Upon completion of this activity, participants should be better able to: Review the clinical significance of the long-term evidence for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC; Identify patients with unresectable HCC who are appropriate for first-line immunotherapy-based combination regimens; and Outline an individualized, long-term treatment plan that balances the risks and benefits of first-line immunotherapy-based combination regimens for patients with unresectable HCC.
Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.
Please visit answersincme.com/GSN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and thoracic surgery discuss chemo-immunotherapeutic approaches in early-stage non–small cell lung cancer. Upon completion of this activity, participants should be better able to: Review the clinical profiles of available and emerging neoadjuvant and perioperative immunotherapy-based approaches for patients with early-stage NSCLC; Identify patients for whom a neoadjuvant or perioperative immunotherapy-based approach is warranted, based on the available and emerging clinical data; and Outline a multidisciplinary strategy to improve outcomes in early-stage NSCLC through the use of neoadjuvant or perioperative immunotherapy-based approaches in appropriate patients.
Please visit answersincme.com/MWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in coagulation disorders discusses the clinical impact of gene therapy in hemophilia A. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of gene therapy in the treatment of hemophilia A; Identify patients with hemophilia A who may be candidates for gene therapy; and Outline patient-centered monitoring strategies to optimize outcomes in patients with hemophilia A undergoing gene therapy.
Please visit answersincme.com/RPM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses available third-line therapies for patients with chronic myeloid leukemia. Upon completion of this activity, participants should be better able to: Describe treatment challenges with available therapeutic options as chronic myeloid leukemia (CML) progresses; Review the available clinical data for third-line agents in CML; and Differentiate between third-line CML treatments based on patient, drug, and disease factors.
Please visit answersincme.com/UJD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in transgender medicine discusses improving approaches to guideline-concordant cervical cancer screening by healthcare professionals in patients who are transgender men or nonbinary. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of low uptake of cervical cancer screening among transgender men (TM) and people who identify as nonbinary (NB); Review key concerns experienced by TM and NB people that result in lower rates of cervical cancer screening; and Identify tailored strategies to enhance acceptance of cervical cancer screening in TM and people who identify as NB.
Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) using PD-1 inhibitors; Review the latest clinical data for first-line PD-1 inhibitor–based therapies in the treatment of patients with R/M HNSCC; and Describe clinical strategies to optimize management of patients with R/M HNSCC treated with PD-1 inhibitors.
Please visit answersincme.com/EKH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses frontline immunotherapy-based combination strategies to improve outcomes in patients with advanced biliary tract cancer. Upon completion of this activity, participants should be better able to: Review the rationale for including immunotherapy as a component of a therapeutic approach for patients with advanced biliary tract cancer (BTC); Describe the clinical profiles of immunotherapy plus chemotherapy combinatorial approaches for the treatment of advanced BTC; and Outline practical strategies to enhance evidence-based care of patients with advanced BTC on a combined immunotherapy plus chemotherapy approach.
Please visit answersincme.com/WGA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of triplet therapy for patients with metastatic hormone-sensitive prostate cancer. Upon completion of this activity, participants should be better able to: Discuss recommended, evidence-based triplet therapies for patients with metastatic hormone-sensitive prostate cancer (mHSPC); Recognize patient and disease factors that can guide the selection of triplet treatment strategies for mHSPC; and Explain how to minimize adverse events for patients being treated with triplet therapy for mHSPC.
Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical profiles of the emerging neoadjuvant-adjuvant immunotherapeutic regimens in patients with resectable melanoma; and Identify patients for whom a neoadjuvant-adjuvant approach may be appropriate based on available clinical evidence.
Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.
Please visit answersincme.com/DEV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses TROP2-directed therapies for patients with non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Outline the rationale for incorporating TROP2-directed therapies into the treatment of patients with advanced NSCLC; Explain the latest clinical data supporting the use of emerging TROP2-directed therapies in the treatment of advanced NSCLC; and Identify strategies to maximize the incorporation of TROP2-directed therapies into treatment plans for patients with advanced NSCLC, as they become available.
Please visit answersincme.com/ZRV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in lung carcinoma discuss the latest data in first-line chemoimmunotherapy for non–small-cell lung cancer.Upon completion of this activity, participants should be better able to: Outline which patients might align with first-line chemoimmunotherapy regimens for advanced NSCLC; Review the clinical profiles of chemoimmunotherapy regimens in the first-line setting for the treatment of advanced NSCLC; and Translate the latest data informing the use of first-line chemoimmunotherapy regimens to individualized care of patients with advanced NSCLC.
Please visit answersincme.com/VET860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the use of adjuvant chemotherapy for patients with early-stage non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Describe the rationale for adjuvant immunotherapy in patients with early-stage non–small-cell lung cancer (NSCLC) following surgery and chemotherapy; Review the clinical profiles of approved and emerging adjuvant immunotherapy regimens in early-stage NSCLC; and Outline factors that optimize integration of adjuvant immunotherapy regimens for early-stage NSCLC into clinical practice.
Please visit answersincme.com/TZQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in clinical oncology discusses optimizing patient outcomes with immunotherapy-based combination approaches in unresectable hepatocellular carcinoma (HCC). Upon completion of this activity, participants should be better able to: Recognize the role of available and recently approved immunotherapy-based combination regimens for the management of unresectable HCC; Outline the practical implications of the clinical trial data evaluating available and recently approved immunotherapy-based combination regimens for unresectable HCC; and Review a personalized approach to optimize patient outcomes on available and recently approved immunotherapy-based combination regimens, thus enhancing quality of life.
Please visit answersincme.com/XJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and urology discuss guideline-recommended systemic treatment options and strategies to optimize long-term care for patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). Upon completion of this activity, participants should be better able to: Recognize unmet needs in the management of VHL disease-associated RCC; Describe the clinical impact of current guideline-recommended systemic treatment options for VHL disease-associated RCC; and Identify strategies to optimize long-term care for patients with VHL disease-associated RCC.
Please visit answersincme.com/XQE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in non–small-cell lung cancer (NSCLC) discuss perioperative immunotherapeutic approaches in patients with resectable NSCLC. Upon completion of this activity, participants should be better able to: Describe the rationale for perioperative immunotherapeutic approaches in patients with resectable NSCLC; Outline the clinical impact of perioperative immunotherapeutic approaches in patients with resectable NSCLC; and Identify practical strategies to optimize the care of patients with resectable NSCLC, based on the current and emerging clinical data.
Please visit answersincme.com/MMD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in multiple myeloma discuss triplet combination therapies and treatment selection in relapsed/refractory multiple myeloma (RRMM). Upon completion of this activity, participants should be better able to: Explain current guideline recommendations to optimize clinical treatment plans for patients with RRMM; Review the clinical implications of the latest data for triplet regimens containing an anti-CD38 monoclonal antibody, proteasome inhibitors, and chemotherapy in special patient populations with RRMM; and Identify additional monitoring strategies for special patient subgroups with RRMM based on the latest clinical evidence and expert guidance.
Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses the use of chimeric antigen receptor (CAR) T cell therapies in B-cell lymphoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory indolent follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Describe the clinical profiles of approved and emerging CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL; and Outline clinical considerations for the use of CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL.
Please visit answersincme.com/TSM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the rationale, latest evidence, and practical considerations for adding a locoregional approach (eg, tumor-treating fields therapy, stereotactic body radiation therapy) to systemic immunotherapy for patients with advanced non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Outline the mechanisms of action of novel locoregional therapies and their combination with immunotherapies to treat advanced NSCLC; Describe the evidence on combining novel locoregional therapies with systemic; Immunotherapy for advanced NSCLC; and Identify practical patient-centered strategies for the evidence-based use of combined locoregional and systemic immunotherapy treatment in advanced NSCLC.
Please visit answersincme.com/MPP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts—a medical oncologist and an oncology nurse practitioner—discuss a multidisciplinary approach to holistic management of hand-foot skin reaction (HFSR) from multikinase inhibitor therapy in patients with colorectal cancer (CRC). Upon completion of this activity, participants should be better able to: Recognize the impact of hand-foot skin reaction (HFSR) in patients being treated with multikinase inhibitors; Discuss the rationale for holistic management of HFSR in patients taking multikinase inhibitors; and Outline strategies for optimal HFSR management, including patient education and practical shared communication strategies to help manage HFSR.
Please visit answersincme.com/KDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the use of neoadjuvant immunotherapies in the treatment of surgically resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the rationale for using neoadjuvant immunotherapies for patients with surgically resectable CSCC; Review the latest evidence on the efficacy and safety of emerging neoadjuvant immunotherapies for patients with surgically resectable CSCC; and Outline clinical strategies to optimize the therapeutic management of surgically resectable CSCC for patients who would be appropriate candidates for neoadjuvant immunotherapies.
Please visit answersincme.com/MHQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss how to optimize the use of oral targeted adjuvant therapy in patients with high-risk, HR+ HER2- early breast cancer. Upon completion of this activity, participants should be better able to: Identify which patients with HR-positive HER2-negative (HR+ HER2-) early breast cancer are at high risk for recurrence; Review the clinical significance of the latest data for targeted adjuvant treatment of HR+ HER2- high-risk early breast cancer; Outline proactive, patient-centered strategies to optimize the care of patients with HR+ HER2- high-risk early breast cancer.
Please visit answersincme.com/HAJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and oncology nursing discuss the clinical profiles of novel targeted therapies for triple negative breast cancer (TNBC) and multidisciplinary strategies for adverse event management to improve patient survivorship. Upon completion of this activity, participants should be better able to: Review the safety profiles of novel targeted treatment options for patients with pretreated advanced triple negative breast cancer (TNBC); Identify multidisciplinary, proactive, adverse event management strategies to enhance outcomes on novel targeted treatment options for pretreated advanced TNBC; and Outline patient-focused, multidisciplinary strategies that can enhance perception of care and on-treatment survivorship for advanced TNBC.
Please visit answersincme.com/ZUU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology and oncology discusses the clinical implications of approved and emerging anti–lymphocyte activation gene-3 (LAG-3)/programmed cell death protein 1 (PD-1) combinations in advanced melanoma. Upon completion of this activity, participants should be better able to: Outline the current unmet treatment needs for patients with advanced melanoma; Review the mechanism of action of anti–LAG-3/PD-1 combinations for the management of advanced melanoma; and Recognize the clinical impact of approved and emerging anti–LAG-3/PD-1 combinations as a therapeutic strategy for the treatment of advanced melanoma.
Please visit answersincme.com/EUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology and oncology discuss the role of cereblon E3 ligase modulators in patients with relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating cereblon (CRBN) E3 ligase modulators (CELMoDs) as therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM); Describe the clinical profiles of emerging CELMoDs for patients with RRMM; and Outline evidence-based strategies to optimize sequencing to CELMoDs for patients with RRMM, as they become available.
Please visit answersincme.com/EEF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck squamous cell carcinoma (HNSCC) discusses the clinical significance of emerging antagonists of inhibitors of apoptosis proteins (IAPs) for patients with HNSCC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for emerging antagonists of IAPs for patients with resectable and unresectable locally advanced (LA) HNSCC; Review the clinical significance of emerging antagonists of IAPs in the treatment of unresectable LA HNSCC, based on the latest efficacy and safety data; and Outline strategies for how antagonists of IAPs may fit into future treatment algorithms for patients with resectable and unresectable LA HNSCC, as they become available.
Please visit answersincme.com/NYN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical significance and evidence for tumor-treating fields in patients with newly diagnosed glioblastoma. Upon completion of this activity, participants should be better able to: Explain the clinical role of tumor-treating fields (TTFields) as a component of a multimodal adjuvant strategy for the management of patients with newly diagnosed glioblastoma multiforme (nGBM); Review the clinical profiles of guideline-recommended adjuvant therapies for patients with nGBM; and Identify strategies to optimize the development of a multimodal adjuvant treatment plan for patients with nGBM.
Please visit answersincme.com/DNA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and dermatology discuss therapeutic options in the first-line treatment of advanced melanoma and the role of the multidisciplinary team in maximizing treatment outcomes. Upon completion of this activity, participants should be better able to: Identify the unmet clinical needs for patients with advanced melanoma; Describe the guideline-recommended first-line treatment strategies for patients with advanced melanoma; and Outline a multidisciplinary, evidence-based therapeutic plan that elevates the efficacy and safety of treatment for patients with advanced melanoma.
Please visit answersincme.com/BCJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses JAK inhibitor therapy for patients with myelofibrosis. Upon completion of this activity, participants should be better able to: Identify early signs of ruxolitinib failure for timely risk stratification of patients with myelofibrosis (MF); Describe the clinical profiles of novel JAK inhibitors for the treatment of patients with MF; and Outline evidence-based strategies to optimize JAK inhibitor therapy for patients with MF.
Please visit answersincme.com/QTQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in multiple myeloma discusses treatment sequencing in relapsed/refractory multiple myeloma (RRMM) and the integration of novel CAR T-cell therapies into the treatment paradigm. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs with current treatments for patients with relapsed/refractory multiple myeloma; Review the significance of the latest clinical data for the use of CAR T cells in pretreated patients with RRMM; and Outline clinical factors that may inform treatment sequencing strategies to optimize outcomes for patients.
Please visit answersincme.com/VKP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses patient profiles, disease factors, and other ways to optimize treatment of patients with advanced gastroesophageal junction and esophageal cancers. Upon completion of this activity, participants should be better able to: Describe the clinical profiles of first-line immunotherapy-based combination regimens for the management of patients with advanced gastroesophageal junction (GEJ) and esophageal cancers; Identify clinical and disease factors that can be used to personalize first-line treatment selection for patients with advanced GEJ and esophageal cancers; Review clinical strategies to optimize quality of care for patients with advanced GEJ and esophageal cancers on immunotherapy-based combination regimens.
Please visit answersincme.com/BRY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses current and emerging strategies to optimize the multidisciplinary care of advanced basal cell carcinoma (BCC) with immunotherapy.Upon completion of this activity, participants should be better able to: Identify patients with BCC for whom a second-line immunotherapy regimen would be appropriate; Review the clinical profiles of immunotherapy-based regimens for the second-line treatment of advanced BCC; and Outline multidisciplinary strategies to optimize the long-term care of patients with advanced BCC who are on an immunotherapeutic approach.
Please visit answersincme.com/ADT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses combination locoregional and systemic therapies in advanced non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Explain the rationale for combining locoregional therapies with immunotherapies to treat advanced NSCLC; Describe the clinical implications for combining novel locoregional therapies with systemic immunotherapy for advanced NSCLC; and Outline practical strategies to optimize treatment for combination therapy in advanced NSCLC.
Please visit answersincme.com/ZZB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses available and emerging consolidation immunotherapies for the treatment of patients with unresectable stage III non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of approved and emerging consolidation immunotherapies in patients with unresectable stage III NSCLC; Identify factors that may inform the use of guideline-recommended and emerging consolidation immunotherapies in patients with unresectable stage III NSCLC; and Recognize the clinical significance of investigational approaches to the use of consolidation immunotherapy in unresectable stage III NSCLC.
Please visit answersincme.com/AJK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloproliferative neoplasms reviews strategies for optimizing outcomes for patients with myelofibrosis. Upon completion of this activity, participants should be better able to: Recognize treatment goals in the management of patients with myelofibrosis; Outline strategies to assess patient risk, including risk stratification of patients with myelofibrosis; and Review the latest clinical implications of Janus kinase (JAK) inhibitors in the treatment of myelofibrosis.
Please visit answersincme.com/WWC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the treatment of hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (aBC) in the real-world setting. Upon completion of this activity, participants should be better able to: Outline the clinical relevance of real-world evidence in the treatment of HR+/HER2- aBC; Review the latest real-world evidence informing the frontline use of CDK4/6 inhibitors in patients with HR+/HER2- aBC; and Identify patient-centered strategies to integrate real-world evidence into optimized care plans for patients with HR+/HER2- aBC.
Please visit answersincme.com/BTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses recent clinical data in dual immunotherapy combinations for non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Discuss the most recent clinical data informing the efficacy and safety of chemotherapeutic regimens, including dual immunotherapy and chemotherapy combination regimens, in advanced non–small-cell lung cancer (NSCLC); Identify strategies for tailoring dual immunotherapy and chemotherapy combination regimens for individualized frontline treatment of advanced NSCLC; and Outline practical approaches to improve quality of life in patients with advanced NSCLC on frontline dual immunotherapy and chemotherapy combination regimens.
Please visit answersincme.com/ZWK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology and oncology discusses B-cell maturation antigen (BCMA)–targeted strategies for the treatment of multiple myeloma. Upon completion of this activity, participants should be better able to: Describe the latest evidence for investigational regimens containing BCMA-targeted immunotherapies for earlier lines of multiple myeloma (MM) treatment; Evaluate the clinical impact of combining late-stage emerging, BCMA-targeted strategies with standard of care (SOC) for earlier lines of MM treatment; and Identify strategies to optimally incorporate novel BCMA-containing therapies into the current treatment paradigm, as they become available, for patients with MM.
Please visit answersincme.com/GDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the clinical impact of approved and emerging combination treatments for advanced melanoma. Upon completion of this activity, participants should be better able to: Identify the unmet treatment needs for patients with advanced melanoma within the current therapeutic landscape; Recognize the mechanism of action of anti-lymphocyte activation gene-3 (anti-LAG-3) plus programmed cell death protein 1 (PD-1) combinations for the treatment of advanced melanoma; and Describe the clinical impact of approved and emerging anti-LAG-3 plus PD-1 combinations for the treatment of advanced melanoma.
Please visit answersincme.com/WZE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses strategies for optimizing immunotherapy in advanced basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Identify patients with advanced BCC who may benefit from immunotherapy; Review the clinical impact of available and emerging immunotherapies for the management of patients with advanced BCC; and Describe practical strategies to manage and monitor patients with advanced BCC on immunotherapy over both the long and short term.
Please visit answersincme.com/GVJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neuro-oncology discusses novel adjuvant therapies for patients with newly diagnosed glioblastoma. Upon completion of this activity, participants should be better able to: Recognize the rationale for combining tumor-treating fields (TTFields) with immunotherapy in the adjuvant treatment of newly diagnosed glioblastoma; Compare the clinical impact of emerging TTFields plus immunotherapy regimens and standard of care in the adjuvant treatment of newly diagnosed glioblastoma; and Outline strategies to personalize the selection of adjuvant therapy for patients with newly diagnosed glioblastoma.
Please visit answersincme.com/PFP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses portable electric field devices. Upon completion of this activity, participants should be better able to: Recognize the rationale for incorporating novel portable electric field therapies into the management of patients with solid tumors; Describe the clinical impact of approved and emerging novel portable electric field devices as part of a patient’s cancer treatment plan; and Outline patient-centered strategies to appropriately integrate novel portable electric field devices into cancer treatment plans for eligible patients.
Please visit answersincme.com/YZZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses estrogen receptor–positive breast cancer. Upon completion of this activity, participants should be better able to: Describe the rationale for investigating oral selective estrogen receptor degraders (SERDs) for the treatment of ER-positive early breast cancer; Review the clinical profiles of emerging oral SERDs for the treatment of patients with ER-positive early breast cancer; and Outline clinical approaches where oral SERDs may be appropriate based on their clinical profile in ER-positive early breast cancer.
Please visit answersincme.com/EZF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the current treatment options for von Hippel-Lindau (VHL) disease. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the management of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC); Describe the clinical impact of current guideline-recommended treatment options for VHL-associated RCC; and Identify strategies to manage adverse events arising from systemic treatment options for VHL-associated RCC.
Please visit answersincme.com/DNQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in urology discusses the gap in prostate cancer outcomes for Black men. Upon completion of this activity, participants should be better able to: Recognize clinical challenges in the management of prostate cancer in Black men; Describe the clinical impact of GnRH antagonists used for androgen deprivation therapy, in comparison to GnRH agonists, in men with advanced prostate cancer; and Outline patient-centered approaches to optimize outcomes for Black men with advanced prostate cancer who are eligible for androgen deprivation therapy.
Please visit answersincme.com/YBC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology discusses the evidence for combining immune checkpoint inhibitors (ICIs) with chemotherapy in the treatment of advanced biliary tract cancer and provides a clinical perspective on the future role of these combinations in the treatment landscape. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for investigating ICI plus chemotherapy combinations in the treatment of advanced biliary tract cancer; Discuss the efficacy and safety of late-stage emerging ICI plus chemotherapy combinations being investigated for the first-line treatment of advanced biliary tract cancer, compared to conventional therapy options; and Summarize clinical considerations for the future use of emerging ICI plus chemotherapy combinations in the first-line treatment of advanced biliary tract cancer.
Please visit answersincme.com/XWC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology, discusses immunotherapy-based combination regimens for the first-line treatment of unresectable HCC. Upon completion of this activity, participants should be better able to: Recognize the therapeutic rationale for immunotherapy-based combination treatment regimens for the management of unresectable hepatocellular carcinoma (HCC) in the first-line setting; Review the clinical implications of the latest efficacy and safety data for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC; and Describe patient selection strategies for available first-line combination immunotherapy-based regimens in unresectable HCC.
Please visit answersincme.com/SSF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology discusses the treatment of unresectable hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Review the rationale for evolving first-line treatment approaches in patients with unresectable hepatocellular carcinoma (HCC); Describe the clinical profiles of emerging first-line dual immunotherapy combination regimens for the treatment of unresectable HCC; and Outline strategies to optimally manage toxicities associated with first-line dual immunotherapy combination regimens for the treatment of unresectable HCC.
Please visit answersincme.com/ACJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses BRCA testing in patients with early-stage breast cancer. This activity also features a patient who shares her experience about genomic testing when being treated for early breast cancer. Upon completion of this activity, participants should be better able to: Recognize the growing importance of comprehensive genomic testing, including BRCA1/2 mutational testing, in patients with early-stage breast cancer; Outline practical, patient-centered strategies to facilitate BRCA1/2 mutational testing in patients with early-stage breast cancer; and Evaluate the clinical significance of the latest trial data for neoadjuvant and adjuvant treatment of patients with BRCA-mutated, early-stage breast cancer.
Please visit answersincme.com/BUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver and biliary cancers discusses the clinical impact of immune checkpoint inhibitors in advanced biliary tract cancer. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating immune checkpoint inhibitor (ICI) plus chemotherapy combinations in the treatment of advanced biliary tract cancer; Describe the clinical impact of late-stage ICI plus chemotherapy combinations for the first-line treatment of advanced biliary tract cancer, in the context of conventional therapy options; and Outline clinical considerations for the future use of ICI plus chemotherapy combinations in the first-line treatment of advanced biliary tract cancer.
Please visit answersincme.com/CHW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology/oncology discusses multiple myeloma. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs with current treatments for patients with relapsed/refractory multiple myeloma (RRMM); Review the role of B-cell maturation antigen (BCMA) as a therapeutic target in multiple myeloma; and Outline clinical considerations for incorporating emerging BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM, based on available evidence.
Please visit answersincme.com/PHE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast oncology discusses the significant of HER2 in the targeted treatment of advanced breast cancer. Upon completion of this activity, participants should be better able to: Identify optimal strategies to assess HER2-low expression in both primary and recurrent tumors in patients with breast cancer; Describe the clinical significance of the latest safety and efficacy data for HER2-targeted antibody drug conjugates in the treatment of patients with HER2-low advanced breast cancer; and Predict the role that HER2-targeted antibody drug conjugates might play in the treatment of pretreated patients with HER2-low advanced breast cancer.
Please visit answersincme.com/ERJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts, one in oncology and another in dermatology, discuss strategies for diagnosis and management of hand-foot skin reaction. Upon completion of this activity, participants should be better able to: Recognize hand-foot skin reaction (HFSR) in patients being treated with multikinase inhibitors; Discuss the rationale for comprehensive management of HFSR in patients taking multikinase inhibitors; and Outline strategies for optimal HFSR management, including patient education to promote self-management.
Please visit answersincme.com/NSY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses neoadjuvant systemic treatment of resectable non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Outline opportunities for improvement over the currently recommended neoadjuvant systemic regimens for patients with resectable NSCLC; Explain the clinical implications of emerging data evaluating chemo-immunotherapeutic approaches for the neoadjuvant treatment of resectable NSCLC; and Describe how to develop a personalized, evidence-based treatment plan for patients with resectable NSCLC.
Please visit answersincme.com/NMC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses rationale for—and clinical impact of—cereblon (CRBN) E3 ligase modulators (CELMoDs) in treating relapsed/refractory multiple myeloma (RRMM), including clinical considerations for their future use. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for investigating novel therapies to address unmet treatment needs for relapsed/refractory multiple myeloma; Review the biologic rationale for targeting cereblon with novel therapies for RRMM; Describe the clinical impact of emerging CRBN E3 ligase modulators in patients with RRMM; and Outline clinical considerations for the integration of CRBN E3 ligase modulators in the future management of RRMM.
Please visit answersincme.com/EUT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses glioblastoma multiforme (GBM). Upon completion of this activity, participants should be better able to: Identify opportunities to personalize adjuvant treatment for patients with newly diagnosed glioblastoma multiforme (GBM); Describe practical approaches to manage adverse events associated with adjuvant therapies in patients with newly diagnosed GBM; and Outline strategies to monitor patients with newly diagnosed GBM on adjuvant therapies to improve patient outcomes.
Please visit answersincme.com/VSA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses how racial disparities may impact the management of Black patients with anemia of chronic kidney disease (CKD) and how to address these disparities. Upon completion of this activity, participants should be better able to: Identify the racial disparities that affect Black patients with anemia of CKD, leading to suboptimal outcomes; Recognize underlying factors contributing to racial disparities in the management of Black patients with anemia of CKD; and Outline strategies to improve the individualized treatment and management of anemia of CKD among Black patients.
Please visit answersincme.com/KAG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert on immunization discusses the mechanisms of COVID-19 vaccines, the clinical impact of viral vector–based vaccines and how to improve communication with patients regarding vaccine uptake. Upon completion of this activity, participants should be better able to: Recognize the mechanism of action of available COVID-19 vaccines; Evaluate the clinical impact of available viral vector–based COVID-19 vaccines; and Apply patient-centered counseling strategies to enhance communication with patients to improve COVID-19 vaccine acceptance.
Please visit answersincme.com/BZG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses new evidence for targeting PD-1/PD-L1 inhibition in locally advanced cervical cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for therapeutically targeting the PD-1/PD-L1 axis to address unmet treatment needs in locally advanced cervical cancer; Describe ongoing studies and preliminary evidence for late-stage emerging PD-1/PD-L1 inhibitors being investigated for the treatment of locally advanced cervical cancer; and Outline current and potential future roles of PD-1/PD-L1 inhibitors in cervical cancer management.
Please visit answersincme.com/AXF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic cancers discusses the potential role of combination poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors (ICIs) in improving outcomes in advanced ovarian cancer.Upon completion of this activity, participants should be better able to: Discuss the clinical rationale for combining PARP inhibitors with ICIs; Review the clinical profile of PARP inhibitors in combination with ICIs for patients with advanced ovarian cancer; and Identify the potential place in therapy for PARP inhibitors in combination with ICIs in advanced ovarian cancer.
Please visit answersincme.com/BTD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses available and emerging frontline dual immunotherapy plus chemotherapy combination regimens for the treatment of patients with advanced non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be able to: Review the role of PD-L1 expression in the selection of frontline immunotherapeutic regimens for patients with advanced NSCLC, with a focus on available and emerging frontline dual immunotherapy and chemotherapy combination regimens; Describe the clinical profiles of available and emerging frontline dual immunotherapy plus chemotherapy combination regimens for the treatment of patients with advanced NSCLC; and Outline strategies to integrate available and emerging dual immunotherapy and chemotherapy combination regimens into frontline settings through optimal patient selection and management.
Please visit answersincme.com/MDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the impact of adjuvant immune checkpoint inhibitors (ICIs) on outcomes in patients with resected early-stage non-small cell lung cancer (NSCLC), and how to optimally integrate them into practice based on recent evidence. Upon completion of this activity, participants should be better able to: Review guideline-recommended adjuvant treatment options for patients with surgically resected early-stage NSCLC; Describe the clinical evidence for novel ICIs being investigated for the adjuvant treatment of surgically resected early-stage NSCLC; and Outline clinical considerations for the use of novel adjuvant ICIs in the management of patients with surgically resected early-stage NSCLC.
Please visit answersincme.com/XRU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck carcinoma discusses unmet therapeutic needs in squamous cell carcinoma of the head and neck and the potential impact of inhibitor of apoptosis proteins on treatment. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs of patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN); Describe the rationale for targeting inhibitor of apoptosis proteins (IAPs) in the development of novel therapies for LA SCCHN; and Review the clinical impact of emerging IAP antagonists in the treatment of LA SCCHN, based on the preliminary efficacy and safety data.
Please visit answersincme.com/YXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the importance of biomarker testing for multiple tumors, as well as the available testing methodologies and best practices to personalize care. Upon completion of this activity, participants should be better able to: Recognize the importance of biomarker testing in improving patient outcomes in multiple cancers; Review biomarker testing methodologies available to evaluate for the presence of actionable mutations and biomarkers; and Outline provider-level, multidisciplinary best practices to optimize biomarker testing in clinical practice.
Please visit answersincme.com/UVN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses advanced melanoma. Upon completion of this activity, participants should be better able to: Describe the clinical profiles for emerging LAG-3 inhibitors as treatment for selected patients with advanced melanoma; Identify patients with advanced melanoma who may benefit from LAG-3 inhibitors based on available evidence; and Explain strategies to monitor the use of LAG-3 inhibitors in patients with advanced melanoma to enhance patient outcomes.
Please visit answersincme.com/SBK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses the role of novel electric field therapies in treating solid tumors. Upon completion of this activity, participants should be better able to: Describe the rationale for incorporating novel electric field therapies into the management of patients with solid tumors; Outline approaches to counsel patients on the use of novel electric field devices as part of the treatment plan for cancer management; and Apply practical strategies to balance the efficacy and safety of novel electric field therapies to maximize patient outcomes.
Please visit answersincme.com/CHA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer management discusses current and future treatment strategies to manage patients with advanced nonmelanoma skin cancer (NMSC), including cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Propose patient and disease-related factors that could help determine the optimal treatment strategies for patients suffering from advanced NMSC; Describe the efficacy and safety of immunotherapies in the management of the most common NMSCs, BCC and CSCC; Identify the potential place of immunotherapies in the treatment plan for patients with NMSC.
Please visit answersincme.com/PAP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in genitourinary oncology discusses targeted treatments for advanced urothelial carcinoma. Upon completion of this activity, participants should be better able to: Review the approved and emerging targeted treatment options for patients with advanced urothelial carcinoma (UC) progressing on first- or second-line of therapy; Describe the available clinical data on targeted treatment options for patients with advanced UC who have progressed on immunotherapy; and Outline evidence-based strategies to optimize outcomes for patients with advanced UC who have progressed on immunotherapy.
Please visit answersincme.com/TNC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of current and emerging selective estrogen receptor degraders (SERDs) in managing patients with estrogen receptor positive breast cancer. Upon completion of this activity, participants should be better able to: Describe the clinical profile of selective estrogen receptor degraders (SERDs) in the management of patients with estrogen receptor positive breast cancer; Outline the role of current and emerging SERDs in the management of estrogen receptor positive breast cancer, based on available clinical evidence; and Discuss clinical factors that are relevant when assessing current and emerging SERD options, based on available clinical evidence.
Please visit answersincme.com/XJF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses current and emerging options for adjuvant treatment of early non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Review guideline-recommended adjuvant treatment options in surgically resected, early-stage NSCLC; Describe the clinical profile of current and emerging adjuvant immunotherapy options for the management of surgically resected, early-stage NSCLC; and Identify potential candidates with surgically resected, early-stage NSCLC for adjuvant treatment with immunotherapy based on patient-specific characteristics.
Please visit answersincme.com/JEB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses evolving first-line therapeutic strategies to optimize the management of patients with unresectable hepatocellular carcinoma (HCC). Upon completion of this activity, participants should be better able to: Review the clinical evidence informing guideline recommendations for the first-line systemic treatment of patients with advanced HCC; Outline individualized first-line treatment plans for patients with advanced HCC, based on patient- and disease-related factors; and Describe long-term management strategies to optimize outcomes and survivorship for patients with advanced HCC receiving systemic first-line therapies.
Please visit answersincme.com/VFW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the evolving role of antibody drug conjugates (ADCs) in managing solid tumors. Upon completion of this activity, participants should be better able to: Describe the mechanism of action of antibody-drug conjugates for cancer treatment; Recognize the potential clinical profile of available antibody-drug conjugates to treat various solid tumor types; and Review how to integrate available antibody-drug conjugates for solid tumors into a therapeutic treatment plan for patients with relevant solid tumors.
Please visit answersincme.com/KAN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiotherapy and medical oncology for thoracic and genitourinary cancers discusses first-line use of new therapeutic options for malignant pleural mesothelioma, including tumor treating fields and immunotherapy. Upon completion of this activity, participants should be better able to: Assess the latest safety and efficacy data for current first-line options used for the treatment of malignant pleural mesothelioma (MPM); Identify patient-, disease-, and drug-related factors that may inform the first-line use of new therapeutic options for MPM; and Use patient-centered care strategies to guide treatment selection and address quality of life concerns.